Zai Lab raised $761 million in a Hong Kong IPO and rose 8.5% in its first trading session to a market cap of $6.8 billion. Zai Lab has been listed on the NASDAQ exchange since 2017. An in-licensing company, Zai's leading drug is Zejula, a PARP inhibitor that is approved in China as a maintenance therapy for ovarian cancer. Its portfolio consists of 15 drug candidates and one device. In addition to in-licensings, Zai is also using internal innovation to discover new products. More details.... Stock Symbols: (NSDQ: ZLAB; HK: 9688) Share this with colleagues: // //